Publications by authors named "Dimitri A Breems"

Claim this Profile
D
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.
Lok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, Fleur Janssen, Laura Oudshoorn-van Marsbergen, Dimitri A Breems

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
Tim R Mocking, Lukas H Haaksma, Tom Reuvekamp, Angèle Kelder, Willemijn J Scholten, Dimitri A Breems

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.
Sjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, Yvette van Norden, Jeroen J W M Janssen, Dimitri A Breems

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Jesse M Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A Breems, Thomas Fischer

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.
Lok Lam Ngai, Diana Hanekamp, Fleur Janssen, Jannemieke Carbaat-Ham, Maaike A M A Hofland, Dimitri A Breems

Blood· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
Jesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, Costa Bachas, Dimitri A Breems

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tim Grob, Adil S A Al Hinai, Mathijs A Sanders, François G Kavelaars, Melissa Rijken, Dimitri A Breems

Blood· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Anita W Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J Biemond, Arjen A van de Loosdrecht, Dimitri A Breems

Blood Adv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.
Katerina Bakunina, Hein Putter, Jurjen Versluis, Eva A S Koster, Bronno van der Holt, Dimitri A Breems

Cancer Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J Biemond, Dimitri A Breems

Blood Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD34CD38 leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
Wendelien Zeijlemaker, Tim Grob, Rosa Meijer, Diana Hanekamp, Angèle Kelder, Dimitri A Breems

Leukemia· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
Robert J Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin, Dimitri A Breems

Leukemia· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Bob Löwenberg, Thomas Pabst, Johan Maertens, Yvette van Norden, Bart J Biemond, Dimitri A Breems

Blood· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.
Guillermo Garcia-Manero, Gary Gartenberg, David P Steensma, Martin R Schipperus, Dimitri A Breems

Am J Hematol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia.
Dimitri A Breems, Wim L J Van Putten, Bob Löwenberg

Blood· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum.
Dimitri A Breems, Bob Löwenberg

Haematologica· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.
Dimitri A Breems, Wim L J Van Putten, Georgine E De Greef, Shama L Van Zelderen-Bhola, Klasien B J Gerssen-Schoorl

J Clin Oncol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia and the position of autologous stem cell transplantation.
Dimitri A Breems, Bob Löwenberg

Semin Hematol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.
Bronno van der Holt, Dimitri A Breems, H Berna Beverloo, Eva van den Berg, Alan K Burnett

Br J Haematol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.
Dimitri A Breems, Bob Löwenberg

Br J Haematol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic index for adult patients with acute myeloid leukemia in first relapse.
Dimitri A Breems, Wim L J Van Putten, Peter C Huijgens, Gert J Ossenkoppele, Gregor E G Verhoef

J Clin Oncol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
Dimitri A Breems, Marc A Boogaerts, Adriaan W Dekker, Wim L J Van Putten, Pieter Sonneveld

Br J Haematol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Dimitri A Breems, Pieter Sonneveld, Rob A de Man, Frank W G Leebeek

Eur J Haematol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis